Study S001982

A Randomized, Open-Label, Long-Term, Parallel-Group, Comparator-Controlled, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Exenatide Twice Daily in Subjects With Type 2 Diabetes Mellitus

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01652716
Acronym: DURATION-NEO-1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 377
Start: 2013-01
Primary completion: 2014-08
Lead sponsor: AstraZeneca
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Exenatide once weekly suspension; DRUG:Exenatide twice daily
Results posted: TRUE
Secondary identifiers: OTHER:MB001-003

Registered primary outcomes

Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28 [Baseline to Week 28]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022632	Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study. Wysham CH, BMJ open diabetes research & care	2020	Randomized trial	PMID 33037036 DOI	cites ClinicalTrials.gov:NCT01652716; registry reference DERIVED:33037036
R0014206	Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. Wysham CH, Diabetes, obesity & metabolism	2018	Randomized trial	PMID 28685973 DOI	cites ClinicalTrials.gov:NCT01652716; registry reference DERIVED:28685973